GILD PE Ratio & Valuation, Is GILD Overvalued

Historical Valuation

Gilead Sciences Inc (GILD) is now in the Fair zone, suggesting that its current forward PE ratio of 14.44 is considered Fairly compared with the five-year average of 11.76. The fair price of Gilead Sciences Inc (GILD) is between 121.05 to 162.48 according to relative valuation method.

Relative Value

Fair Zone

121.05-162.48

Current Price：146.63

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Gilead Sciences Inc (GILD) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Gilead Sciences Inc (GILD) has a current Price-to-Book (P/B) ratio of 7.01. Compared to its 3-year average P/B ratio of 5.58, the current P/B ratio is approximately 25.58% higher. Relative to its 5-year average P/B ratio of 5.03, the current P/B ratio is about 39.51% higher. Gilead Sciences Inc (GILD) has a Forward Free Cash Flow (FCF) yield of approximately 6.07%. Compared to its 3-year average FCF yield of 7.84%, the current FCF yield is approximately -22.55% lower. Relative to its 5-year average FCF yield of 9.10%, the current FCF yield is about -33.26% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for GILD competitors is 6.51, providing a benchmark for relative valuation. Gilead Sciences Inc Corp (GILD.O) exhibits a P/S ratio of 5.04, which is -22.58% above the industry average. Given its robust revenue growth of 4.70%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of GILD increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of GILD in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is GILD currently overvalued or undervalued?

What is Gilead Sciences Inc (GILD) fair value?

GILD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Gilead Sciences Inc (GILD) is between 121.05 to 162.48 according to relative valuation method.

How does GILD's valuation metrics compare to the industry average?

The average P/S ratio for GILD's competitors is 6.51, providing a benchmark for relative valuation. Gilead Sciences Inc Corp (GILD) exhibits a P/S ratio of 5.04, which is -22.58% above the industry average. Given its robust revenue growth of 4.70%, this premium appears unsustainable.

What is the current P/B ratio for Gilead Sciences Inc (GILD) as of Mar 10 2026?

As of Mar 10 2026, Gilead Sciences Inc (GILD) has a P/B ratio of 7.01. This indicates that the market values GILD at 7.01 times its book value.

What is the current FCF Yield for Gilead Sciences Inc (GILD) as of Mar 10 2026?

As of Mar 10 2026, Gilead Sciences Inc (GILD) has a FCF Yield of 6.07%. This means that for every dollar of Gilead Sciences Inc's market capitalization, the company generates 6.07 cents in free cash flow.

What is the current Forward P/E ratio for Gilead Sciences Inc (GILD) as of Mar 10 2026?

As of Mar 10 2026, Gilead Sciences Inc (GILD) has a Forward P/E ratio of 14.44. This means the market is willing to pay $14.44 for every dollar of Gilead Sciences Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Gilead Sciences Inc (GILD) as of Mar 10 2026?

As of Mar 10 2026, Gilead Sciences Inc (GILD) has a Forward P/S ratio of 5.04. This means the market is valuing GILD at $5.04 for every dollar of expected revenue over the next 12 months.

GILD Valuation